This year, the program, chaired by Drs. David Morrow and Ziad Mallat, will provide an in depth discussion of established and emerging biomarkers as effective, non-invasive tools to enhance the detection and management of cardiovascular diseases. The appropriate contemporary clinical use of available biomarkers will be reviewed, as will the pathophysiological insights, technologic advances, and development strategies guiding biomarker discovery. This program is designed to be of interest to cardiologists, internists, emergency physicians, and researchers.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), French Embassy, Inserm, Roche Laboratories, Siemens Medical Solutions Diagnostics and Dade Behring, do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, French Embassy, Inserm, Roche Laboratories, Siemens Medical Solutions Diagnostics and Dade Behring. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.